Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Feb;24(1):e76-e77.
doi: 10.3747/co.24.3413. Epub 2017 Feb 27.

Trastuzumab in metastatic breast cancer after complete remission: an expensive commitment for an entire life?

D Bernardi  1 , M Stefani  1 , M Boccalon  1 , C Raiti  1
Affiliations
Comment

Trastuzumab in metastatic breast cancer after complete remission: an expensive commitment for an entire life?

D Bernardi et al. Curr Oncol. 2017 Feb.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22:1063–70. doi: 10.1200/JCO.2004.06.557. - DOI - PubMed
    1. Viel E, Arbion F, Barbe C, Bougnoux P. Prolonged complete response after treatment withdrawal in her2-overexpressed, hormone receptor–negative breast cancer with liver metastases: the prospect of disappearance of an incurable disease. BMC Cancer. 2014;14:690. doi: 10.1186/1471-2407-14-690. - DOI - PMC - PubMed
    1. Oguz A, Rahatli S, Altundag O, Altundag K. Trastuzumab in metastatic breast cancer after complete remission: how long is enough? Med Oncol. 2015;32:211. doi: 10.1007/s12032-015-0648-1. - DOI - PubMed
    1. Montemurro F, Prat A, Rossi V, et al. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in her2-positive metastatic breast cancer. Mol Oncol. 2014;8:20–6. doi: 10.1016/j.molonc.2013.08.013. - DOI - PMC - PubMed
    1. Yeo B, Kotsori K, Mohammed K, Walsh G, Smith IE. Long-term outcome of her2 positive metastatic breast cancer patients treated with first-line trastuzumab. Breast. 2015;24:751–7. doi: 10.1016/j.breast.2015.09.008. - DOI - PubMed

LinkOut - more resources